COVID-19: France cancels purchase of Merck’s’Molnupiravir‘
-With disappointing test effects-
[Paris / Milan December 22, Reuters]
France
Health Minister Belan
-Cancellation of purchase of “Molnupiravir”-
December 22, “Developed by Merck and Ridgeback Biotherapeutics, USA,
Canceled the purchase order for “Molnupiravir”.
instead of,
Consider purchasing “Pax Robid”.
“We would like to procure Paxrovid, a drug made by Pfizer in the US, at the end of January next year.”
Around Molnupiravir:
Merck in November
“Molnupiravir is less effective in preventing hospitalization and death than originally expected,” he said.
According to the clinical trial results, “the effect of molnupiravir is only 30%.”
“I wasn’t happy with the results of my recent research,” Veran told BFM TV.
Merck:
So far, it has sold and supplied Molnupiravir to more than 30 countries.
France:
had ordered 50,000 Molnupiravir.
According to Belan, there are no costs associated with canceling an order.
Pfizer’s Pax Robid:
“Test results show that the effect of preventing hospitalization and death of high-risk patients is close to 90%” is available.
Reuters
https://jp.reuters.com/article/health-coronavirus-france-merck-idJPKBN2J127J
New Corona: U.S. Authors Approve Pfizer’s Corona Drink: Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXZQOGN22EU50S1A221C2000000/
France cancels order for Merck’s COVID-19 antiviral drug
Reuters
PARIS/MILAN, Dec 22 (Reuters)
France has cancelled
its order for Merck & Co’s (MRK.N) COVID-19 antiviral drug following disappointing trial data
and hopes instead
to receive Pfizer’s (PFE.N) competing drug before the end of January, the health minister said on Wednesday.
France is the first country
to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought,
reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.
https://www.reuters.com/world/europe/france-cancels-order-mercks-covid-19-antiviral-drug-2021-12-22/